Beyond BCMA: GPRC5D & FcRH5

Loss of B-cell maturation antigen (BCMA) poses a large challenge, with many newer therapies having this target. Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, explains how this issue is being addressed with research, and where believes the science will take us. Specifically mentioned is the targeting of GPRC5D, FcRH5, and the use of combinatorial approaches. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.